Monitor the final prospectus supplement for exact pricing and net proceeds. The company's cash burn rate (Q3 operating expenses $10.2M) suggests this capital raise is critical for near-term survival. Watch for any update on the CGuard Prime for CAS PMA supplement submission timeline and U.S. sales ramp.
Drug in focus
NSPR drug pipeline →CGuard Prime
◆ Mixed Named in this press release- Impact
- Phase
- Approved (FDA PMA)
- Time to market
- CGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.
- Next catalyst
- NDA filing · Dec 2026
What to watchThe next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.6441entry
- T+1 · yesterday −6.85%α −4.94% · $0.6000
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InspireMD priced a public offering of 7.34M shares, pre-funded warrants for 50.35M shares, and common warrants for 43.27M shares, with an underwriter option for additional securities. The offering follows yesterday's Q3 earnings release showing an 11% revenue decline and a $9.8M net loss, and a preliminary prospectus supplement filed the same day. Proceeds are for R&D, sales, marketing, and working capital.
Key Facts
- Priced offering of 7,342,308 common shares, pre-funded warrants for 50,350,000 shares, and common warrants for 43,269,231 shares
- Underwriters have 30-day option to purchase additional 8,653,846 shares and/or pre-funded warrants and/or common warrants for 6,490,384 shares (15% of total)
- Offering expected to close on or about November 16, 2026
- Lake Street Capital Markets is sole book-running manager
- Proceeds to be used for R&D, sales and marketing, working capital, and general corporate purposes
- Q3 2026 revenue declined 11.1% YoY to $2.24M; net loss of $9.76M
- Cash and equivalents fell from $54.2M (Dec 2025) to $19.2M (Sep 2026)
- Market cap is $37M, making the offering highly dilutive relative to current shares outstanding
Financial Impact
Offering includes up to 57.7M shares (common + pre-funded) plus 43.3M common warrants; at $0.80/share (Nov 11 close), gross proceeds could exceed $46M before warrants; dilution is massive relative to current 46M shares outstanding (pre-offering).
Risk Factors
- Extreme dilution: pre-funded warrants alone represent 50.35M shares, more than doubling the current share count
- Company has substantial doubt about ability to continue as a going concern (stated in risk factors)
- Q3 revenue decline and cash burn rate indicate ongoing operational challenges
- Voluntary U.S. recall of CGuard Prime delivery system continues to impact U.S. revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402557 |
Track record
29 reports on NSPR
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
- Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 13, 20264d ago Press Release Bearish 6/10 Viewing Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 8-K Bullish 7/10 No price data
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers